Shares in biotech Orthocell have soared after a leading scientific publication published data on Orthocell's collaborative research on regenerating cartilage.
Orthocell shares closed up 11.5 cents, or 24.73 per cent, at 58 cents.
Its projects include the fabrication of human tendon outside of the body for full tendon replacement.
Perth-based Orthocell says publication of the research data in the Journal of Tissue Engineering and Regenerative Medicine further validates its products derived from cells cultivated in a "cell factory".
The paper published in the journal showed that proteins derived from cells cultivated in the cell factory helped regenerate defective cartilage in rabbits.
"As the population ages and cartilage injuries become more prevalent, doctors and patients are seeking out treatments to alleviate symptoms that affect their mobility and quality of life," Orthocell chief executive Paul Anderson said on Thursday.
"It may also be a promising early treatment in an ageing population with more widespread cartilage loss such as those that occur in osteoarthritis."
More than 500,000 cartilage surgeries are undertaken in the US each year.
Share
